Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics, 1st Edition

Author :
By Daniel J. Lenihan, MD, FACC and Douglas B. Sawyer, M.D., Ph.D., FACC
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.  Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing r ...view more
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.  Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.  This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.
ISBN :
9781455711017
Publication Date :
28-07-2011
Stock Status :
Please allow 7-10 working days for delivery
Earn 10 Points
Add to Cart
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.  Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.  This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

Author Information
By Daniel J. Lenihan, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and Douglas B. Sawyer, M.D., Ph.D., FACC, Maine Medical Center Department of Cardiac Services Portland, ME, USA